Unlocking Real-World Data with AI

Real4Reg – Unlocking Real-World Data with AI

Real4Reg is a consortium of ten European institutions which aims to promote the use of real-world data (national healthcare registers and claims data) to support the regulatory decisions about medicines. Real4Reg will take advantage of ground-breaking technologies such as artificial intelligence and machine learning.
The structure and approach of our project aim to facilitate the implementation of the effective use of real-world data in regulatory decision-making and health technology assessment.

hand and virtual screen
© Adobe Stock/WrightStudio

Data & Methods

Real4Reg will use data sources from four European countries (Denmark, Finland, Germany, and Portugal) and will develop solutions to address the data analytical needs of regulatory agencies.
From a methodological point of view, the project is aligned with the decision-making process in regulatory agencies, which can be broadly broken down into the pre-authorisation, evaluation, and post-authorisation phases of the product lifecycle.

Use Cases

Description of Study population: breast cancer, ALS

Real4Reg will assess the value of real-world data from national healthcare registers and claims data in generating high-quality, accessible, population-based information on breast cancer and amyotrophic lateral sclerosis (considering the diagnosis, treatment, and outcomes).

woman at laptop
© Adobe Stock/Andrey Popov

Historical controls and synthetic data: breast cancer, ALS

Real4Reg will demonstrate how the real-world data can contribute to questions that are not typically answered by clinical trials, due to ethical or practical issues. These questions need to be answered for regulatory evaluation and health technology assessment, in the improvement of external validity and statistical power and precision.

persons with papers in their hand in front of a laptop
© Adobe Stock/VideoFlow

Safety: Fluoroquinolones

The overall objective of this use case is to prepare a good practice example for safety analyses of real-world data for the post-authorisation stage and to improve methods for risk estimation in observational data. Real4Reg will also evaluate the impact of regulatory warnings on the use of broad-spectrum antibiotics.

hand holding pills
© Adobe Stock/Maksim

Effectiveness and drug repurposing: SGLT2 Inhibitors

Real4Reg will prepare a good practice example for drug effectiveness and drug repurposing analyses of real-world data for the drug post-authorisation stage. The case of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors will be analysed. These antidiabetic medicines have shown beneficial effects on cardiovascular outcomes in recent years.

female doctor
© Adobe Stock/Prostock-studio

Latest News

Latest News

Who we are

Our consortium assembles ten partners from six different European countries with experience in the field of RWD analyses, including experts from regulatory agencies and health technology assessment bodies, academia, and patient organisations.

Read more

A project for the Patients

Real4Reg integrates two patient organisations to incorporate the patients’ perspectives and expectations along its work.

Read more

Newsletter